Performance of Service-Oriented Architecture (SOA)

2019 ◽  
pp. 785-801
Author(s):  
Deepika Dubey ◽  
Deepanshu Dubey ◽  
Uday Pratap Singh
Keyword(s):  
Rheumatoid Arthritis ◽  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Mental Illness ◽  
Renal Failure ◽  
Chronic Diseases ◽  
Service Oriented Architecture ◽  
Service Oriented ◽  
Data Passing

A service-oriented architecture is combination of services having different platforms for implementation. These services are combined, used by, and communicate with each other. The communication is done by massage or data passing. Communication is done by interacting with each other based on different platforms. Chronic diseases are long-term illness that require observation with heavy treatments by the doctors and special attention by family members. Chronic diseases are Alzheimer's disease, Addiction, Autoimmune diseases, Blindness, Rheumatoid arthritis, Chronic renal failure, Chronic Kidney Disease, Deafness and hearing impairment, Hypertension, Mental illness, Thyroid disease, Blood Pressure abnormalities.

Performance of Service-Oriented Architecture (SOA)

2017 ◽  
pp. 327-343
Author(s):  
Deepika Dubey ◽  
Deepanshu Dubey ◽  
Uday Pratap Singh
Keyword(s):  
Rheumatoid Arthritis ◽  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Mental Illness ◽  
Renal Failure ◽  
Chronic Diseases ◽  
Service Oriented Architecture ◽  
Service Oriented ◽  
Data Passing

A service-oriented architecture is combination of services having different platforms for implementation. These services are combined, used by, and communicate with each other. The communication is done by massage or data passing. Communication is done by interacting with each other based on different platforms. Chronic diseases are long-term illness that require observation with heavy treatments by the doctors and special attention by family members. Chronic diseases are Alzheimer's disease, Addiction, Autoimmune diseases, Blindness, Rheumatoid arthritis, Chronic renal failure, Chronic Kidney Disease, Deafness and hearing impairment, Hypertension, Mental illness, Thyroid disease, Blood Pressure abnormalities.

scholarly journals Associations between antenatal prednisone exposure and long-term cortisol and cortisone concentrations in children born to women with rheumatoid arthritis: results from a nationwide prospective cohort study

RMD Open ◽  
2019 ◽  
Vol 5 (1) ◽  
pp. e000852 ◽  
Author(s):  
Hilal Ince-Askan ◽  
Erica L T van den Akker ◽  
Yolanda B de Rijke ◽  
Elisabeth F C van Rossum ◽  
Johanna M W Hazes ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Blood Pressure ◽  
Body Composition ◽  
Prospective Study ◽  
Disease Activity ◽  
Low Dose ◽  
Reference Group ◽  
Negative Consequences ◽  
Hair Cortisol

ObjectivesTo identify whether children with antenatal prednisone exposure have chronically elevated cortisol and cortisone concentrations, an altered body composition or higher blood pressure. In addition, to identify whether maternal rheumatoid arthritis disease (RA) activity is associated with these alterations.MethodsIn this prospective study, 56 children (mean age=10.0 years) with and 61 children (mean age=9.6 years) without antenatal prednisone exposure, born to women with RA, were included. Hair cortisol and cortisone were analysed using liquid chromatography–tandem mass spectrometry. Linear regression models were built to analyse differences between the two groups, corrected for relevant covariates. Hair cortisol concentrations were also compared between the study population and an age-matched healthy reference group(n=150 children, mean age=9.8 years).ResultsHair cortisol and cortisone concentrations were similar in children with and without antenatal prednisone exposure (median cortisol 1.14 pg/mg (IQR 0.67–1.75) and 1.15 pg/mg (IQR 0.65–2.21) and median cortisone 6.76 pg/mg (IQR 5.42–8.86) and 7.40 pg/mg (IQR 5.39–10.73), respectively). Antenatal prednisone exposure and maternal RA disease activity were also not associated with body composition or blood pressure. Hair cortisol concentrations were not different in children born to mothers with RA compared with children from the reference group.ConclusionThis, in its kind, large and unique long-term prospective study demonstrates that low-dose antenatal prednisone exposure and maternal RA disease activity are not associated with negative consequences in prepubertal childhood. The findings of this study are reassuring and support the assumption that low-dose maternal prednisone use during pregnancy is safe for the offspring, at least until the age of approximately 10 years.

scholarly journals Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion

Pharmaceutics ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 714
Author(s):  
Sung Hun Bae ◽  
Sun-Young Chang ◽  
So Hee Kim
Keyword(s):  
Rheumatoid Arthritis ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Hepatic Metabolism ◽  
Term Treatment ◽  
Concentration Time ◽  
Long Term Treatment ◽  
Total Body ◽  
Body Clearance

Tofacitinib is a Jak inhibitor developed as a treatment for rheumatoid arthritis. Tofacitinib is metabolized mainly through hepatic CYP3A1/2, followed by CYP2C11. Rheumatoid arthritis tends to increase renal toxicity due to drugs used for long-term treatment. In this study, pharmacokinetic changes of tofacitinib were evaluated in rats with gentamicin (G-ARF) and cisplatin-induced acute renal failure (C-ARF). The time-averaged total body clearance (CL) of tofacitinib in G-ARF and C-ARF rats after 1-min intravenous infusion of 10 mg/kg was significantly decreased by 37.7 and 62.3%, respectively, compared to in control rats. This seems to be because the time-averaged renal clearance (CLR) was significantly lower by 69.5 and 98.6%, respectively, due to decreased creatinine clearance (CLCR). In addition, the time-averaged nonrenal clearance (CLNR) was also significantly lower by 33.2 and 57.4%, respectively, due to reduction in the hepatic CYP3A1/2 and CYP2C11 subfamily in G-ARF and C-ARF rats. After oral administration of tofacitinib (20 mg/kg) to G-ARF and C-ARF rats, both CLR and CLNR were also significantly decreased. In conclusion, an increase in area under plasma concentration-time curves from time zero to time infinity (AUC) of tofacitinib in G-ARF and C-ARF rats was due to the significantly slower elimination of tofacitinib contributed by slower hepatic metabolism and urinary excretion of the drug.

Patterns of alcohol consumption among people with major chronic diseases

2019 ◽  
Vol 25 (2) ◽  
pp. 163 ◽  
Author(s):  
Thi Thu Le Pham ◽  
Sarah Callinan ◽  
Michael Livingston
Keyword(s):  
Mental Illness ◽  
Chronic Disease ◽  
Alcohol Consumption ◽  
Chronic Diseases ◽  
Household Survey ◽  
Drinking Patterns ◽  
Risky Alcohol ◽  
National Drug ◽  
Increased Risk

Risky alcohol use places those with existing chronic conditions at increased risk of medical complications. Yet, there is little research assessing the alcohol consumption among this group. The aim of this study is to assess the prevalence of risky drinking among people with a range of chronic diseases. As part of the 2013 National Drug Strategy Household Survey (NDSHS), 22684 Australians aged ≥18 years answered questions about their experience of chronic diseases and their drinking patterns. Nearly 18% (CI: 17.2–19.3) of people with chronic disease reported drinking at a long-term risky level, roughly the same rate as those without chronic disease (19.3%, (CI: 18.6–20.2)). Nearly one-quarter, 24% (CI: 23.0–25.3), of people with chronic diseases drank at levels of increased short-term risk, significantly less than the rest of the sample. Respondents with mental illness were more likely to drink at risky levels than the rest of the sample, while the reverse was true of those with diabetes. Overall, those with chronic diseases have similar drinking patterns to the rest of the population, despite increased risks associated with this consumption. Regular screening and subsequent brief interventions for those with chronic disease, particularly mental illness and cancer, are recommended.

Anaesthesia of the patient with chronic kidney disease

2020 ◽  
Vol 25 (11) ◽  
pp. 268-276
Author(s):  
Oscar Bautista Díaz-Delgado ◽  
Briony Alderson
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Renal Failure ◽  
Cardiac Output ◽  
Kidney Disease ◽  
The Body ◽  
Renal Physiology ◽  
Successful Management ◽  
Emergency Procedures ◽  
Routine Procedures

Chronic kidney disease is common, particularly in geriatric animals. General anaesthesia is usually required for routine procedures (dental prophylaxis, ovariohysterectomy or castration) and emergency procedures, which may have profound effects on the body, especially on cardiac output, subsequent blood pressure and on the perfusion of different vital organs. It is essential to understand the effects of renal dysfunction on the patient, as well as the effects that anaesthesia and surgery may have on the kidneys. The understanding of renal physiology, along with the effect of drug choices, is key to successful management of chronic renal failure.

Sign in / Sign up

Export Citation Format

Share Document